Equities

PRLX

US69916A1051

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2022	Parallax Health Sciences Inc. Announces Executive Changes	CI
2022	Parallax Health Sciences Inc. Terminates Sonia Choi as Interim CEO	CI

Parallax Health Sciences, Inc. Updates Progress on Proprietary COVID-19 Rapid Test

March 24, 2020 at 07:00 am EDT

Parallax Health Sciences, Inc. announced that it has selected the antigens and antibodies that it will use as the markers for its rapid Coronavirus ('COVID-19') screen test used on its FDA Cleared & Patented Target Diagnostics Test Platform.

Latest news about PARX HEAL

Parallax Health Sciences Inc. Announces Executive Changes	22-03-28	CI
Parallax Health Sciences Inc. Terminates Sonia Choi as Interim CEO	22-03-28	CI
Parallax Health Sciences, Inc. Appoints Sonia Choi as Interim Chief Executive Officer	21-09-29	CI
Parallax Health Sciences, Inc. Announces Executive Changes	21-08-23	CI
Parallax Health Sciences Inc. Announces Resignation of Paul R. Arena as Chief Executive Officer	21-07-13	CI
Parallax Health Sciences Inc. Announces Management Changes	21-07-13	CI
Parallax Health Sciences, Inc. Announces Resignation of Capt. E. William Withrow Jr. from its Board and Chair of the Compensation Committee, Deputy Chair of the Audit Committee and Co-Chair of the Governance Committee	21-04-08	CI
Parallax Health Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-05-18	CI
Parallax Health Sciences, Inc. Auditor Raises 'Going Concern' Doubt	20-05-17	CI
Parallax Health Sciences, Inc. Announces Executive Changes	20-04-09	CI
Parallax Health Sciences, Inc. Launches Secure Good Health Outcomes Telehealth Application for Immediate Free Download	20-03-25	CI
Parallax Health Sciences, Inc. Updates Progress on Proprietary COVID-19 Rapid Test	20-03-24	CI
Parallax Health Sciences, Inc. Receives Approval on its Registration Into U.S. Government's System for Award Management,	20-03-16	CI
Parallax Health Sciences, Inc. announced that it expects to receive $5 million in funding	20-02-09	CI
Parallax Health Sciences, Inc. Announces Resignation of David Appell as Chief Operating Officer	20-02-07	CI
Parallax Health Sciences Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-18	CI
Parallax Health Sciences Inc. Provides Earnings Guidance for Year End of 2020	19-11-18	CI
Parallax Health Sciences, Inc. acquired 19% stake in Global Career Networks, Inc for for $1 million.	19-09-18	CI
Parallax Health Sciences Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-20	CI
Parallax Health Sciences Announces Licensing Agreement with Healthpointe Solutions	19-07-19	CI
Parallax Health Sciences, Inc. Executes an 8% Senior Secured Note in the Principal Sum of $220,000	19-07-12	CI
Parallax Health Sciences Announces Strategic Initiative to Invite Third Party Development for Its Digital Connected Health Platform Software Ecosystem	19-06-28	CI
Parallax Health Sciences Behavioral Health Division Announces Development of Compass-ASD Version 2.0, its Data Driven Mobile Application	19-06-24	CI
Parallax Health Sciences Announces Initiative to Obtain a 510(K) Clearance for its Fotodigm® Enabled Remote Patient Monitoring Platform	19-06-20	CI
Parallax Health Sciences, Inc. Appoints David Appell as Chief Operating Officer	19-06-10	CI

Chart PARX HEAL

Duration

Period

More charts

Company Profile

Parallax Health Sciences, Inc. focuses on personalized patient care through the use of the Company's Compound Pharmacy (Roxsan, Inc.) and eventually through the diagnostic testing platform capable of diagnosing and monitoring various health issues. The Company's segments include Retail Pharmacy Services (RPS) and Corporate. The RPS segment provides a range of pharmacy services, including retail, compounding and fertility medications. The Corporate segment provides management and administrative services to support the Company. The RPS segment dispenses prescription drugs, both through local channels by direct delivery, as well as mail order. The RPS segment also sells an assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, seasonal merchandise and convenience foods, through the Company's pharmacy. It holds interests in Quality of Life Peace of Mind (QOLPOM). The QOLPOM Hub is a personal medication dispensing and remote monitoring solution.

Sector

More about the company